Thursday, January 24, 2013
Disruption of enteric microbiota occurs
in inflammatory bowel diseases, but whether this is a cause or result of the
condition is unclear. Now, European researchers have shed light on the process
by showing that a deficiency in an immune system-related receptor, NOD2,
can disrupt enteric microbiota and set the stage for colitis and
Bugs as drugs
With the causal relationship established,
Chamaillard said the group now is screening for probiotic bacterial strains
that could normalize enteric microbial populations in the IBD setting.
Lou, K.-J. SciBX 6(3); doi:10.1038/scibx.2013.52 Published online Jan.
A. et al. J. Clin. Invest.; published online Jan. 2, 2013;
doi:10.1172/JCI62236 Contact: Mathias Chamaillard, Pasteur Institute in
Lille, Lille, France e-mail: email@example.com
2. Saleh, M. &
Trinchieri, G. Nat. Rev. Immunol. 11, 9-20 (2011)
3. Scanlan, P.D. et al.
J. Clin. Microbiol. 44, 3980-3988 (2006)
4. Manichanh, C. et al.
Gut 55, 205-211 (2006)
J. et al. Gastroenterology 138, 2101-2114.e5 (2010)
AND INSTITUTIONS MENTIONED
AbbVie Inc. (NYSE:ABBV), Chicago, Ill.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Pasteur Institute in Lille, Lille, France
PureTech Ventures, Boston, Mass.
Second Genome Inc., San Francisco, Calif.
(Euronext:UCB), Brussels, Belgium
The University of North Carolina at Chapel Hill School of
Medicine, Chapel Hill,
Vedanta Biosciences Inc., Boston, Mass.